Skip to content

Study · Animal study (in vivo) · mouse · 2010

3 results

Oxytocin attenuates atherosclerosis and adipose tissue inflammation in socially isolated ApoE-/- mice.

Nation DA, Szeto A, Mendez AJ, Brooks LG, Zaias J, Herderick EE, Gonzales J, Noller CM, Schneiderman N, McCabe PM

Psychosomatic medicine5 Apr 2010Cited by 52 (Europe PMC)

PMID20368478 (opens in a new tab)PMCIDPMC4784697 (opens in a new tab)DOI10.1097/psy.0b013e3181d74c48 (opens in a new tab)PepBankPUB-20368478
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In socially isolated apoE-/- mice, oxytocin infusion caused no group difference in plasma lipids compared with vehicle.

    In plain wordsIn mice, oxytocin did not change blood fat levels compared with vehicle.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma lipids
    Study

    Mousen = 43

    Socially isolated apoE-/- mice
    Comparator
    Vehicle
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · osmotic minipump · 12 weeksAs given in this study (Mouse).

    Source sentences

    Summary
    There were no group differences in plasma lipids.
    1 context sentence
    Summary · context
    A total of 43, 12-week-old, apoE(-/-) mice were surgically implanted with osmotic minipumps containing OT (n = 23) or vehicle (n = 20).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In socially isolated apoE-/- mice, oxytocin-treated animals had significantly less atherosclerosis in the thoracic aorta than vehicle-treated animals.

    In plain wordsIn mice, oxytocin treatment led to less artery plaque in the chest aorta than vehicle.

    Peptide
    Oxytocin
    Outcome
    DecreaseAtherosclerosis in the thoracic aorta
    Study

    Mousen = 43

    Socially isolated apoE-/- mice
    Comparator
    Vehicle
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · osmotic minipump · 12 weeksAs given in this study (Mouse).

    Source sentences

    Summary
    OT-treated animals displayed significantly less atherosclerosis in the thoracic aorta (p < .05).
    1 context sentence
    Summary · context
    A total of 43, 12-week-old, apoE(-/-) mice were surgically implanted with osmotic minipumps containing OT (n = 23) or vehicle (n = 20).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In socially isolated apoE-/- mice, adipose tissue from oxytocin-treated animals secreted significantly less IL-6 over 6 hours than tissue from vehicle-treated animals.

    In plain wordsIn mice, fat tissue from oxytocin-treated animals released less of the inflammation marker IL-6 than tissue from vehicle-treated animals.

    Peptide
    Oxytocin
    Outcome
    DecreaseAdipose tissue IL-6 secretion
    Study

    Mousen = 24

    Socially isolated apoE-/- mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · osmotic minipump · 12 weeksAs given in this study (Mouse).

    Source sentences

    Summary
    Adipose tissue samples taken from OT-treated animals secreted significantly less IL-6 over 6 hours (p < .01).
    2 context sentences
    Summary · context
    After 12 weeks of treatment, animals were killed, and samples of adipose tissue were dissected from a subset of OT-treated (n = 12) and vehicle-treated (n = 12) animals and incubated in culture media for 6 hours.
    Summary · context
    A total of 43, 12-week-old, apoE(-/-) mice were surgically implanted with osmotic minipumps containing OT (n = 23) or vehicle (n = 20).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.